A Review of Research on China's Centralized Drugs Bulk-buying Platform for Public Welfare

Wanru Li

doi:10.54097/k9fr0x86

Authors

Wanru Li

DOI:

https://doi.org/10.54097/k9fr0x86

Keywords:

public welfare; Centralized drugs bulk-buying platform; Research review.

Abstract

Inflated drug prices have always been a problem in the circulation of medicines in China, and in recent years, the relevant departments in China have formulated a series of policies to control drug prices, one of the strongest and most effective of which is to carry out centralized procurement of medicines. The state has also introduced a series of related policies around the centralized procurement of drugs, including the establishment of a centralized procurement platform for drugs. Therefore, this paper focuses on the concept of centralized drugs bulk-buying platform, the current development status, functions and advantages, and the review of related literature, puts forward the research deficiencies of the existing literature, and looks forward to the direction of future research, with a view to enriching the research on centralized drugs bulk-buying platform.

Downloads

Download data is not yet available.

References

Chen W M, Yang S F, Chen Z Y, et al. Discussion on the Construction of Digitalized Control Platform for Collectively Procured Medicines and Related Issues[J]. Hospital Management Forum, 2023, 40(01): 61-63+22.

Chen M X, Cong L X, He J J, et al. Analysis of the development status and strategy of China's pharmaceutical GPO[J]. Chinese Journal of Health Policy, 2019, 12(11):34-38.

Sohu.com. China's Southwest and Northwest Drugs and Medicine Centralized Purchasing Platform - Yudu Hui Drug Circulation Supply Chain [EB/OL]. [2022-05-17]. https://www.sohu.com/a/548028483_121370209

Yang C. Anti-monopoly thinking of China's drug group procurement model--Taking Shanghai GPO monopoly agreement case as an example[J]. Market Regulation, 2018(6):70-72.

Jiao T T, Feng Y Z. Analysis of Influencing Factors and Countermeasures of Basic Drug Allocation and Distribution Segment[J]. China Pharmacy, 2012，23(16): 1474-1476.

Zhang X X, Hou W H, Shen C L, He Q. Willingness to Participate in Centralised Purchasing, Pharmaceutical Companies' Bargaining Power and Drug Market Performance[J]. Chinese Journal of Management Science,2017,25(07):113-122.

Ahmadi A, Pishvaee M S, Heydari M. How group purchasing Organisations influence healthcare-product supply chains? An analytical approach[J]. Journal of the Operational Research Society, 2018:1-14.

Hu Q, Schwarz L B, Uhan N A. The impact of group purchasing organizations on healthcare-product supply chains[J]. Manufacturing & Service Operations Management, 2012, 14(1): 7-23.

Wu L, Guo Q, Nie J J. Research on the procurement strategy of the pharmaceutical supply chain under price cap regulation[J/OL]. Journal of Industrial Engineering and Engineering Management:1-12[2023-04-20].

Safaei A S, Heidarpoor F, Paydar M M. A novel mathematical model for group purchasing in healthcare[J]. Operations Research for Health Care,2017,15: 82-90.

Ye G L, Cheng L. Market Competition Effects of Drug Group Purchasing Organizations--A Theoretical Analysis Based on China's GPO Pilot[J]. Journal of Sun Yat-sen University(Social Science Edition),2017,57(06):167-182.

Yang Y, He J J, Zou X, et al. Analysis of the Effectiveness of Centralized Purchasing of Drugs in Shenzhen on Reducing Drug Prices [J]. Chinese Health Resources, 2019, 22(06): 445-448.

Guan X D, Guo Z G, Xin X X, et al. Comparative analysis of centralized bidding and procurement methods for essential drugs by province in China[J]. Chinese Journal of Health Policy, 2014, 7(11): 19-23.

Du W X, Zhang S Y, You S C, et al. Research on Text Analysis of China's Centralized Band Purchasing Policy for Medicines Based on Policy Tools [J]. Chinese Pharmaceutical Affairs, 2023, 37(12): 1341-1351.

Jiang C S, Qi P, Guo D. Historical Changes and Reform Development Trends of China's Centralized Purchasing System for Drugs[J]. China Health Insurance,2022(04):5-11.

Tang Y Q, Li Y M, Cheng X Z, et al. Analysis of centralized drug procurement policy implementation based on the policy implementation system model - A practical study in Province N [J]. Chinese Journal of Health Policy,2023,16(09):29-35.

Li J, Mao Z F, Li T, et al. Multi-policy analysis of Chinese drug procurement in public hospitals[J]. Wuhan University Journal (Philosophy & Social Science), 2015, 68(04): 134-137.

Li H Q, Zhuang Y L, Fan C M. Research on formation mechanism of “Extremely Expensive Drugs”and regulatory policy based on grounded theory[J]. Chinese Public Administration, 2020, 419(05): 140-145.

Guan Z J, Chen X, Ye X Q. The analysis of institutional transformation and internal logic evolution of medical services supply in China[J]. Chinese Public Administration, 2017, No.385(07): 73-80.

Wang C C, Zha Z Y. Has the comprehensive medical reform pilot alleviated the problems of the accessibility and affordability of health care ?[J]. Public Finance Research, 2021, No.466(12): 79-92.

Herr A. Quality and welfare in a mixed duopoly with regulated prices: the case of a public and a private hospital[J]. German Economic Review, 2011, 12(4): 422-437.

Eggleston K, Yip W. Hospital competition under regulated prices: application to urban health sector reforms in China[J]. International Journal of health care finance and economics, 2004, 4: 343-368.

Li J, Liu F, Tan C L, et al. Fuzzy Comprehensive Evaluation of Public Hospital Public Welfare in Sichuan Province Based on Patient Perspective[J].Medicine and Society, 2019, 32(08):39-43+71.

Godager G, Wiesen D. Profit or patients’health benefit? Exploring the heterogeneity in physician altruism[J]. Journal of health economics, 2013, 32(6): 1105-1116.

Brekke K R, Siciliani L, Straume O R. Competition and waiting times in hospital markets[J]. Journal of Public Economics,2008, 92(7): 1607-1628.